89Bio

3 stories about 89Bio
רוש ROCHE

Roche strikes $3.5 billion deal for U.S.-Israeli biotech 89bio

18.09.25|CTech
Founded in 2018 from Teva’s pipeline, the biotech firm is set to become a centerpiece in Roche’s obesity strategy.
נאסדק

Teva-Linked Biotech Company 89Bio Files for Nasdaq IPO

15.10.19|CTech
Israel and San Francisco-based 89Bio raised a $60 million series A in October 2018
מייקל היידן מחקר ו פיתוח טבע

Former Teva Executives Raise $60 Million for Metabolic Disorders Venture

28.10.18|Lilach Baumer
The company’s pipeline of biologic and small molecule drug candidates was acquired from Teva